1.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 35 and under Sponsor: Other Protocol IDs: MT2000-18, 9504M09637, NCT00176878
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: Over 60 Sponsor: Other Protocol IDs: 012000, NCT00382759
|
|
4.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CLB-9011, CAN-NCIC-CL1, E-C9011, SWOG-9108, CALGB-9011, CL1
|
|
5.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: EORTC-20921
|
|
6.
|
Phase: Phase III Type: Treatment Status: Closed Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1813.00, NCI-2009-01532, P01CA078902, FHCRC-1813.00, 5666, NCT00075478
|
|
7.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAM314, 2004-000149-39, NCT00086580
|
|
8.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 102-14, BO17072, NCT00090051
|
|
9.
|
Phase: Phase III Type: Treatment Status: Completed Age: over 18 Sponsor: Other Protocol IDs: PRIMA, NCT00140582
|
|
10.
|
Phase: Phase III Type: Treatment Status: Completed Age: 17 and under Sponsor: Other Protocol IDs: TRIAL, TRIAL Relapsed AML 2001/01, NCT00186966
|
|
11.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000454560, GCLLSG-CLL-8, EU-20560, ML17102, GCLLSG-CLL-8/ML17/02, NCT00281918
|
|
12.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL1, EU-20548, GCLLSG-138, MEDAC-GCLLSG-CLL1, NCT00262782
|
|
13.
|
Phase: Phase III Type: Treatment Status: Closed Age: 65 to 79 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL5, EU-20557, MEDAC-GCLLSG-CLL5, GCLLSG-73, NCT00262795
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL4, EU-20538, GCLLSG-153, ISRCTN75653261, MEDAC-GCLLSG-CLL4, NCT00276848
|
|
15.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL6, EU-20558, AMGEN-GCLLSG-CLL6, MEDAC-GCLLSG-CLL6, NCT00416910
|
|
16.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NIP-03-007, NCT00254163
|
|
17.
|
Phase: Phase III Type: Treatment Status: Closed Age: 65 and under Sponsor: NCI, Other Protocol IDs: 1992.00, NCI-2010-00737, P01CA078902, K23HL084054, P01CA018029, P01HL036444, FHCRC-1992.00, 6170, NHLBI-K23-HL084054-01A1, NCT00322101
|
|
18.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000537685, U10CA031946, CALGB-10501, NCT00513747
|
|
19.
|
Phase: Phase III Type: Treatment Status: Closed Age: 1 to 21 Sponsor: NCI, NHLBI Protocol IDs: 467, BMT CTN 0501, 5 U01 HL69294-05, FHCRC-2128.00, NCT00412360
|
|
20.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 65 and under Sponsor: Other Protocol IDs: 2005-0366, NCT00469144
|
|
21.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTI-CRRI-0807003, CRRI 0807003, NCT00551239
|
|
22.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000577580, CLL-2007-FMP, INCA-RECF0496, EudraCT-2007-000327-18, RECF0496, NCT00564512
|
|
23.
|
Phase: Phase III Type: Treatment Status: Closed Age: 60 and over Sponsor: Other Protocol IDs: CHUBX 2007/13, NCT00590837
|
|
24.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CDR0000616169, GCLLSG-CLL10, 2007-007587-21, CLL10, EUDRACT-2007-007587-21, EU-20883, ROCHE-GCLLSG-CLL10, NCT00769522
|
|
25.
|
Phase: Phase III Type: Treatment Status: Completed Age: 15 to 69 Sponsor: Other Protocol IDs: C-005, NCT00774280
|